IXICO plc has completed a placing, subscription and retail offer
October 2024 — IXICO plc has raised US$5 million (£4.05 million) through an over-subscribed placing, subscription and retail offer, issuing 42,621,508 new ordinary shares at 9.5 pence per share, a premium to the price at the time. This important fundraising initiative enables the company to further its pioneering work in neuroscience through advanced imaging and data analytics.
IXICO is a leading medical imaging services provider, specializing in supporting clinical trials for pharmaceutical and biotech companies. With a global network of imaging sites and its custom TrialTracker platform, IXICO offers advanced imaging analytics and digital biomarker services for a variety of neurological diseases, including Alzheimer’s, Huntington’s, Parkinson’s and rare neurological disorders. The company is committed to regulatory compliance and has extensive experience in early-phase clinical development and extended longitudinal studies.
Our role in the transaction
Oaklins Cavendish, one of Oaklins’ member firms in the UK, advised IXICO plc on this transaction.
Talk to the deal team
Related deals
Mattina Holding has sold a 5% stake in Gens Aurea via accelerated bookbuild
Mattina Holding S.A. (DVC Partners) has sold a 5% stake in Italian company Gens Aurea S.p.A. through an accelerated bookbuild, raising approximately US$69.96 million.
Learn moreVeremark has completed a secondary share sale
Veremark, the global workplace trust company, has completed an employee and early investor secondary share sale, on the London Stock Exchange’s (LSE) Private Securities Market (PSM), valuing the company at over US$133 million in enterprise value. Crowdcube, Europe’s leading private market liquidity platform, managed the transaction.
Learn moreKatalyst Diagnostics has been acquired by Cruinn Diagnostics
Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.
Learn more